Cologuard® revenue and completed tests increased 87 percent to $90.3 million and 186,000
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Exact Sciences (EXAS) Tops Q1 EPS by 4c
April 26, 2018 4:22 PM EDTExact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.33), $0.04 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $90.3 million versus the consensus estimate of $86.93 million.
"The Exact Sciences team delivered strong growth to start the year by remaining relentlessly focused... More
